List of Excipients in Branded Drug TYLENOL 8 HR ARTHRITIS PAIN

Subscribe to access the full database, or Start Trial
Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Kenvue Brands LLC	TYLENOL 8 HR ARTHRITIS PAIN	acetaminophen	50580-783	CARNAUBA WAX
Kenvue Brands LLC	TYLENOL 8 HR ARTHRITIS PAIN	acetaminophen	50580-783	CELLULOSE, MICROCRYSTALLINE
Kenvue Brands LLC	TYLENOL 8 HR ARTHRITIS PAIN	acetaminophen	50580-783	HYDROXYETHYL CELLULOSE
Kenvue Brands LLC	TYLENOL 8 HR ARTHRITIS PAIN	acetaminophen	50580-783	HYPROMELLOSE
Kenvue Brands LLC	TYLENOL 8 HR ARTHRITIS PAIN	acetaminophen	50580-783	MAGNESIUM STEARATE
>Company	>Tradename	>Ingredient	>NDC	>Excipient	>Potential Generic Entry

Generic Drugs Containing TYLENOL 8 HR ARTHRITIS PAIN

Subscribe to access the full database, or Start Trial
Company	Ingredient	NDC	Excipient
Kenvue Brands LLC	acetaminophen	50580-575	CELLULOSE, MICROCRYSTALLINE
Kenvue Brands LLC	acetaminophen	50580-575	HYDROXYETHYL CELLULOSE
Kenvue Brands LLC	acetaminophen	50580-575	HYPROMELLOSE
Kenvue Brands LLC	acetaminophen	50580-575	MAGNESIUM STEARATE
Kenvue Brands LLC	acetaminophen	50580-575	POLYETHYLENE GLYCOL
>Company	>Ingredient	>NDC	>Excipient

What are the Most Frequently-Used Excipients in TYLENOL 8 HR ARTHRITIS PAIN?

Subscribe to access the full database, or Start Trial
# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	HYDROXYETHYL CELLULOSE
1	HYPROMELLOSE
1	MAGNESIUM STEARATE
1	POLYETHYLENE GLYCOL
># Of NDCs	>Excipient

TYLENOL 8 HR Arthritis Pain Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

TYLENOL 8 HR Arthritis Pain is an extended-release, 650 mg acetaminophen caplet marketed for temporary relief of minor arthritis pain. Its commercial differentiation depends primarily on sustained-release performance, dosing convenience, brand recognition, and retail distribution rather than active-ingredient exclusivity. The product has no biologic or biosimilar exposure, and its regulatory pathway is generally associated with the U.S. over-the-counter analgesic monograph rather than an Orange Book-listed prescription product.

The main commercial opportunities are private-label extended-release acetaminophen, improved swallowability, abuse-resistant or tamper-evident packaging, senior-friendly dosing systems, global reformulation, and differentiated excipient systems that preserve 8-hour release while reducing manufacturing cost.

What is TYLENOL 8 HR Arthritis Pain?

TYLENOL 8 HR Arthritis Pain contains 650 mg of acetaminophen per caplet. The product is intended for adults and children age 12 years and older and is labeled for temporary relief of minor pain associated with arthritis, as well as other minor aches and pains depending on the product presentation.[1]

Product attribute	Description
Brand	TYLENOL 8 HR Arthritis Pain
Active ingredient	Acetaminophen
Strength	650 mg per caplet
Dosage form	Extended-release caplet
Dosing concept	2 caplets every 8 hours, subject to label limits
Therapeutic category	OTC analgesic and antipyretic
Primary user segment	Adults with recurring minor pain, including arthritis pain
Brand owner	Kenvue Inc. and related operating entities
U.S. regulatory route	OTC drug monograph framework
Biologic status	Not applicable
Orange Book status	Generally not treated as an Orange Book-listed prescription drug

The product’s value proposition is reduced dosing frequency compared with immediate-release acetaminophen. That advantage is delivered through the tablet matrix, coating, compression profile, particle-size distribution, and dissolution behavior.

What excipients are used in TYLENOL 8 HR Arthritis Pain?

Public product labeling identifies the active ingredient and inactive ingredients for the marketed presentation. Reported excipient categories for TYLENOL 8 HR Arthritis Pain include cellulose-based materials, hypromellose, magnesium stearate, povidone, pregelatinized starch, sodium starch glycolate, and coating or polishing materials such as carnauba wax.[1]

The precise formulation can vary by market, manufacturing site, package configuration, and product revision. Excipients should therefore be confirmed against the current package insert, DailyMed record, and commercial regulatory dossier before use in an abbreviated new drug application or private-label program.

Functional role of the principal excipient classes

Excipient class	Likely technical function	Commercial relevance
Hypromellose	Matrix former and release-controlling polymer	Central to 8-hour dissolution performance
Cellulose derivatives	Diluent, binder, matrix support, or processing aid	Supports tablet hardness and reproducibility
Pregelatinized starch	Binder and disintegrant support	Improves compaction and manufacturability
Sodium starch glycolate	Disintegrant	Controls tablet breakup and release onset
Povidone	Binder and granulation aid	Improves powder cohesion and content uniformity
Magnesium stearate	Lubricant	Reduces tooling friction and ejection force
Carnauba wax	Surface polish or coating component	Improves appearance and handling
Film-coating materials	Protection, swallowability, color, and branding	Supports patient acceptance and product recognition

The key technical challenge is balancing extended release with reliable tablet integrity. Excessive matrix strength can delay drug release and create batch-to-batch dissolution variability. Excessive disintegrant activity can cause premature release and undermine the 8-hour claim.

How does the extended-release excipient system work?

Extended-release acetaminophen products generally use a hydrophilic matrix approach. After ingestion, water penetrates the tablet and hydrates the polymer. The hydrated polymer forms a gel barrier. Acetaminophen then diffuses through the gel and leaves the matrix as the outer layer erodes or disperses.

The release profile depends on:

Hypromellose viscosity grade
Polymer concentration
Acetaminophen particle size
Tablet porosity
Compression force
Lubrication level
Granulation method
Tablet dimensions
Coating thickness
Storage humidity
Dissolution medium and agitation conditions

A formulation developer seeking to compete with TYLENOL 8 HR Arthritis Pain would need to reproduce the labeled dosing interval and demonstrate consistent dissolution across relevant test conditions. Matching the inactive-ingredient list alone would not establish therapeutic or regulatory equivalence.

Which excipient levers have the greatest technical value?

The most commercially relevant formulation levers are polymer selection, polymer viscosity, matrix porosity, and manufacturing process control.

Hydrophilic polymers with different viscosity grades can alter the early release phase and terminal release rate without changing the active ingredient. Direct compression may reduce manufacturing steps, but wet granulation can improve content uniformity and compactibility when high drug loading or poor powder flow creates problems.

A competing formulation could also use:

A multilayer tablet with separate loading and release zones
A coated extended-release core
A combination of hydrophilic and hydrophobic release-control agents
A less hygroscopic polymer system
A smaller caplet geometry
A low-friction coating designed for easier swallowing
A polymer blend that reduces sensitivity to compression force

The commercial risk is that any change in polymer system may require new dissolution development, stability studies, and regulatory support.

What patents protect TYLENOL 8 HR Arthritis Pain?

The active ingredient, acetaminophen, is long off patent. Any original composition-of-matter protection has expired, and acetaminophen is widely available from multiple manufacturers.

The likely protection profile is therefore divided into four categories:

Protection category	Current significance
Acetaminophen composition patent	No meaningful current exclusivity
Basic extended-release formulation patents	Any relevant early patents are likely expired or commercially weak
Brand and trade dress	Potentially important for consumer recognition
Manufacturing know-how	Potentially important if formulation and process controls are difficult to reproduce

A precise patent clearance review should distinguish the current marketed formulation from historical sustained-release acetaminophen patents. Patent families covering controlled-release matrices, tablet coatings, compression methods, or dosing regimens may still appear in historical searches, but expiration, terminal disclaimers, prosecution history, claim scope, and claim construction determine practical relevance.

No current patent number should be treated as protecting the TYLENOL 8 HR Arthritis Pain commercial product without a claim chart linking the patent claims to the actual formulation, process, or labeled use.

When does TYLENOL 8 HR Arthritis Pain lose exclusivity?

TYLENOL 8 HR Arthritis Pain does not have a conventional prescription-drug exclusivity date comparable to a new molecular entity or a 30-month Paragraph IV litigation stay.

Its commercial exclusivity is based mainly on:

Brand recognition
Retail shelf position
Advertising
Consumer trust
Packaging and trade dress
Distribution relationships
Formulation know-how
Regulatory execution
Product availability

The acetaminophen active ingredient is generic. Competing manufacturers can market extended-release acetaminophen products if they meet the applicable FDA requirements and avoid enforceable third-party patents, trademarks, and trade dress.

What is the FDA regulatory status of TYLENOL 8 HR Arthritis Pain?

Acetaminophen analgesic products are regulated under the FDA’s OTC monograph system for internal analgesic, antipyretic, and antirheumatic products. The relevant framework includes the FDA’s OTC monograph provisions and 21 C.F.R. Part 343.[2][3]

The principal regulatory issues for a competing 650 mg extended-release acetaminophen product include:

Correct active ingredient and strength.
Permitted indication and labeling.
Maximum daily dose.
Age restrictions.
Liver toxicity warnings.
Alcohol-related warnings.
Duplicate-acetaminophen warnings.
Child-resistant and senior-friendly packaging considerations.
Stability and dissolution performance.
Manufacturing compliance under current good manufacturing practices.

The FDA’s 2020 final rule converting many OTC monograph procedures to the administrative order system changed the procedural framework for future monograph amendments, but it did not create exclusivity for the TYLENOL brand.[4]

What is the Orange Book status of TYLENOL 8 HR Arthritis Pain?

The product is generally not positioned like an FDA-approved prescription product with an Orange Book patent listing and Paragraph IV certification pathway. OTC monograph products typically do not receive the same Orange Book treatment as approved prescription drugs.

As a result:

There is generally no Orange Book-listed patent portfolio equivalent to that of a prescription extended-release product.
A generic manufacturer does not ordinarily challenge the brand through a standard Paragraph IV ANDA filing directed at an Orange Book listing.
Patent disputes would more likely involve formulation patents, process patents, trademarks, trade dress, or commercial misrepresentation claims.
Market entry may proceed through the applicable OTC regulatory route if the product meets FDA requirements.

Are there Paragraph IV challenges to TYLENOL 8 HR Arthritis Pain?

No conventional Paragraph IV challenge is expected to be central to this product because TYLENOL 8 HR Arthritis Pain is an OTC acetaminophen product rather than a typical Orange Book-listed prescription drug.

A competitor could still face patent litigation if a third party asserts a relevant formulation or manufacturing patent. That litigation would not necessarily follow the classic brand-versus-ANDA structure. The absence of a prominent Paragraph IV pathway lowers one procedural barrier to entry, but it does not eliminate patent-clearance requirements.

What formulation patents could affect a competing product?

The highest-risk patent areas are not the acetaminophen molecule itself. They are formulation and manufacturing claims involving:

Extended-release matrix systems
Specific hypromellose grades or polymer ratios
Multi-phase release profiles
Coated matrix tablets
Tablet hardness and porosity ranges
Acetaminophen particle engineering
Manufacturing methods that improve content uniformity
Packaging systems that protect against moisture
Specific dosing regimens or arthritis-related indications

A formulation patent is commercially relevant only if its claims cover the proposed product or process and remain enforceable in the target jurisdiction. The analysis should include U.S., European, Canadian, Australian, Japanese, and selected emerging-market family members.

What generic launch risks exist for TYLENOL 8 HR Arthritis Pain?

The principal launch risks are regulatory and commercial rather than active-ingredient patent risks.

Risk	Assessment
Active-ingredient patent risk	Low
Paragraph IV risk	Low or not applicable
Formulation patent risk	Product- and jurisdiction-specific
FDA monograph compliance risk	Moderate
Dissolution equivalence risk	Moderate to high
Liver-safety labeling risk	High if warnings are incomplete
Trademark risk	High if branding is similar
Trade-dress risk	Moderate to high
Consumer substitution risk	Moderate
Retail access risk	High for new entrants
Manufacturing scale-up risk	Moderate

Extended-release dosage forms are more difficult to reproduce consistently than immediate-release tablets. A competitor can use the same active ingredient and still fail because of early dose dumping, slow terminal release, poor stability, excessive tablet size, or inconsistent dissolution after storage.

Which companies are challenging the TYLENOL 8 HR Arthritis Pain position?

The competitive set includes private-label retailers, generic-drug manufacturers, and branded analgesic companies. Potential competitors include products sold under store brands such as CVS Health, Walgreens, Walmart, Costco, Amazon, and regional pharmacy labels, as well as generic acetaminophen manufacturers.

The relevant competitive products may use labels such as:

Acetaminophen 650 mg extended release
Arthritis pain acetaminophen
8-hour acetaminophen
Long-acting acetaminophen
Joint-pain acetaminophen

The most credible competitive threat comes from private-label products with comparable packaging, lower prices, and placement near the TYLENOL brand. Private-label manufacturers can avoid substantial consumer-acquisition costs by relying on retailer traffic and established distribution.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can target the product category through performance-based formulation systems rather than commodity ingredient sales.

Extended-release polymer systems

A supplier could offer a validated hypromellose platform optimized for high-dose acetaminophen matrices. The value proposition would be lower dissolution variability, shorter development time, and improved scale-up from laboratory compression to commercial equipment.

Direct-compression systems

Acetaminophen has high drug loading and can present flow and compactibility challenges. Co-processed excipients combining a compressible filler, binder, and disintegrant could reduce granulation requirements and improve production efficiency.

Senior-oriented dosage forms

Arthritis pain patients may have difficulty swallowing large caplets. Opportunities include:

Smaller high-density caplets
Smooth low-friction coatings
Easy-open packaging
Unit-dose blister packs
Clearly differentiated dosing cards
Alternative extended-release tablets with lower tablet mass

Any smaller dosage form must preserve the acetaminophen dose and dissolution profile.

Moisture-control solutions

Humidity can affect tablet hardness, polymer hydration, dissolution, and coating integrity. High-barrier bottles, desiccant systems, induction seals, and moisture-resistant blister films can reduce stability risk.

Taste and mouthfeel

Although caplets are swallowed intact, coating selection affects mouthfeel, handling, and swallowability. A smooth coating with controlled friction may produce a commercial advantage without altering the core release mechanism.

How does TYLENOL 8 HR Arthritis Pain compare with immediate-release acetaminophen?

Attribute	TYLENOL 8 HR Arthritis Pain	Immediate-release acetaminophen
Dosing frequency	Lower frequency	More frequent
Release profile	Extended	Rapid
Formulation complexity	Higher	Lower
Dissolution burden	More demanding	Standard immediate release
Tablet development risk	Moderate to high	Low to moderate
Manufacturing cost	Generally higher	Generally lower
Patient convenience	Higher for recurring pain	Lower for prolonged coverage
Generic competition	Strong	Very strong
Brand differentiation	Dosing convenience and recognition	Price, availability, and recognition

The extended-release segment can command a price premium, but the premium is vulnerable to store-brand substitution. A competitor must offer either a lower cost, better swallowability, better packaging, or stronger retail execution.

How strong is the TYLENOL 8 HR Arthritis Pain patent estate?

The patent estate is likely weak as a barrier to entry when measured against conventional pharmaceutical exclusivity. The strongest barriers are brand-related and operational.

Estate component	Relative strength
Acetaminophen molecule	Very low
Basic 650 mg strength	Very low
Extended-release concept	Low to moderate, depending on claims and expiration
Current formulation claims	Requires product-specific claim mapping
Manufacturing know-how	Moderate if process-sensitive
Trademark	Strong if used by a confusingly similar entrant
Trade dress	Potentially strong against close packaging copies
Retail distribution	Strong commercial barrier
Consumer loyalty	Strong commercial barrier

The absence of strong molecule or Orange Book exclusivity makes the product accessible to competitors. The difficulty lies in reproducing performance, securing distribution, and building consumer recognition.

What licensing deals could support market entry?

Licensing opportunities are more likely to involve formulation technology, excipient platforms, contract manufacturing, or regional brand rights than acetaminophen intellectual property.

Potential deal structures include:

A development license for an extended-release polymer platform
A contract manufacturing agreement for 650 mg caplets
A private-label supply agreement with a national retailer
A regional license for arthritis-pain branding
A packaging and serialization partnership
A co-development agreement for senior-friendly dosage forms

A technology license should define ownership of dissolution data, process parameters, regulatory filings, improvements, stability data, and country-specific approvals. The economic value is likely to reside in speed to market and manufacturing reliability rather than patent exclusivity.

What geographic opportunities exist?

The United States is attractive because of brand demand and large OTC distribution, but competition is intense. Canada, Australia, the United Kingdom, and European markets may offer opportunities for extended-release paracetamol products, subject to national labeling and regulatory rules.

International development must account for:

Acetaminophen versus paracetamol naming
Country-specific dose limits
Different OTC classification rules
Local monograph requirements
National trademark availability
Packaging-language requirements
Pediatric warnings
Liver-safety labeling
Restrictions on arthritis-related claims

A single global formulation may not be optimal. Excipient permissions, tablet appearance requirements, and dissolution expectations can vary by jurisdiction.

What revenue exposure does TYLENOL 8 HR Arthritis Pain create?

Kenvue does not generally disclose revenue for TYLENOL 8 HR Arthritis Pain as a standalone SKU. Reported consumer-health revenue is aggregated across broader brand and geographic categories.[5]

The product’s financial exposure is therefore best assessed through channel-level indicators:

Retail sell-through
Average selling price
Unit volume
Promotion frequency
Store-brand price gap
Pharmacy and mass-retail distribution
E-commerce search ranking
Repeat purchase rate
Arthritis-season demand
Product availability and out-of-stock rates

The brand’s principal economic defense is portfolio scale. Even if a competitor erodes share in extended-release acetaminophen, the broader TYLENOL franchise can retain distribution and consumer recognition across multiple dosage forms.

Key Takeaways

TYLENOL 8 HR Arthritis Pain is a 650 mg extended-release acetaminophen caplet.
Its commercial differentiation comes from 8-hour dosing, brand equity, and distribution, not active-ingredient patent protection.
The critical excipient is the release-controlling polymer system, supported by binders, disintegrants, lubricants, and coating materials.
Generic and private-label competition faces low active-ingredient patent risk but meaningful dissolution, stability, manufacturing, trademark, and retail risks.
Paragraph IV litigation is generally not the primary entry mechanism because the product is an OTC monograph product rather than a conventional Orange Book-listed prescription drug.
The strongest commercial opportunities are private-label extended-release acetaminophen, senior-friendly dosage forms, co-processed excipients, moisture-control packaging, and regional licensing.
No biosimilar issue exists because acetaminophen is a small-molecule drug.
Kenvue’s product-level revenue is not separately disclosed, so exposure should be estimated through retail volume, price, distribution, and substitution data.

FAQs About TYLENOL 8 HR Arthritis Pain Excipient and Market Strategy

What is the main release-controlling excipient in TYLENOL 8 HR Arthritis Pain?

Hypromellose is the principal release-controlling polymer category associated with the extended-release matrix. Its grade, concentration, and interaction with tablet porosity determine much of the dissolution profile.

Can a company launch a store-brand version of TYLENOL 8 HR Arthritis Pain?

Yes, subject to FDA requirements, applicable OTC rules, patent clearance, trademark clearance, compliant labeling, and satisfactory stability and dissolution data. The competing product cannot copy TYLENOL branding or trade dress in a confusing manner.

Is acetaminophen 650 mg extended release protected by an Orange Book patent?

TYLENOL 8 HR Arthritis Pain is generally not treated as an Orange Book-listed prescription product. A competitor should not assume that an Orange Book Paragraph IV pathway applies.

What is the largest formulation risk for an extended-release acetaminophen competitor?

The largest technical risk is failure to maintain the intended release profile across manufacturing scale, compression-force variation, storage conditions, and dissolution testing. Dose dumping or excessive release delay can compromise the product.

Are biosimilars relevant to TYLENOL 8 HR Arthritis Pain?

No. Acetaminophen is a synthetic small-molecule active ingredient. The relevant competitors are generic, private-label, and branded extended-release acetaminophen products.

References

Kenvue Inc. (n.d.). TYLENOL 8 HR Arthritis Pain: Drug facts label. U.S. product labeling and DailyMed materials.
U.S. Food and Drug Administration. (2022). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. Electronic Code of Federal Regulations.
U.S. Food and Drug Administration. (2023). Acetaminophen, aspirin, and combination products labeling and regulatory information. FDA.
U.S. Food and Drug Administration. (2020). Over-the-counter monograph drug products: Final administrative order procedures. Federal Register.
Kenvue Inc. (2024). Annual report for the fiscal year ended December 31, 2023. Kenvue Investor Relations.

More… ↓

⤷ Start Trial